Bausch Health, Canada Inc. announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% w/w), is now available to patients through BC PharmaCare, the public drug program of British Columbia. ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada. ARAZLO is the only tazarotene acne treatment available in a lotion formulated with PRISMATREXTM technology (formulation with known hydrating and moisturizing effects, which may alleviate dryness of skin).1 Retinoids like tazarotene are a core component of acne treatment.

Providing the treatment in a lotion form helps limit the dryness and irritation that has historically been a barrier to the long-term use of tazarotene by patients. Approximately 5.6 million Canadians are impacted by acne3 and often need to try different treatment options to find one that is effective for them. ARAZLO is produced by Bausch Health, Canada for Canadian patients and for export at the company's manufacturing facility in Laval, Quebec.